fae

Resources

Guides and research on menopause and endometriosis treatment.

Menopause & hormone therapy

Benefits, risks, and the FDA’s 2026 boxed-warning changes. Treatment depends on your symptoms and medical history.

  • Hormone therapy: a patient guide

    The Menopause Society

    Explains systemic and vaginal estrogen, benefits and risks, and why a progestogen is generally needed with systemic estrogen if you have a uterus.

  • The 2022 hormone therapy position statement

    The North American Menopause Society (now The Menopause Society), 2022

    Guidance on benefits, risks, and patient selection. Starting after age 60 or more than 10 years after menopause has a less favorable benefit–risk balance.

  • Low-dose estradiol for hot flashes and night sweats

    JAMA Internal Medicine, 2014

    In 339 women, symptom frequency fell 53% with low-dose oral estradiol versus 29% with placebo over eight weeks. The trial does not establish long-term safety.

  • Hormone therapy safety: what changed

    U.S. Office on Women’s Health

    Explains which warnings changed. Heart disease and breast cancer risks remain in labeling; the endometrial-cancer boxed warning remains for systemic estrogen-only products.

  • FDA updates hormone therapy boxed warnings

    U.S. Food and Drug Administration, February 12, 2026

    The February 2026 announcement removing cardiovascular disease, breast cancer, and probable dementia statements from six products’ boxed warnings.

Endometriosis treatment

Hormonal medicines can reduce pain but do not cure endometriosis. Treatment depends on symptoms, side effects, and pregnancy plans; some people need surgery.